1. Home
  2. RTX vs REGN Comparison

RTX vs REGN Comparison

Compare RTX & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RTX Corporation

RTX

RTX Corporation

N/A

Current Price

$195.50

Market Cap

281.7B

Sector

Industrials

ML Signal

N/A

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

N/A

Current Price

$777.20

Market Cap

68.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RTX
REGN
Founded
1934
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
281.7B
68.8B
IPO Year
1994
1995

Fundamental Metrics

Financial Performance
Metric
RTX
REGN
Price
$195.50
$777.20
Analyst Decision
Buy
Buy
Analyst Count
12
25
Target Price
$204.25
$830.16
AVG Volume (30 Days)
3.5M
529.5K
Earning Date
04-21-2026
04-29-2026
Dividend Yield
1.57%
0.55%
EPS Growth
39.72
8.19
EPS
3.08
18.95
Revenue
$80,738,000,000.00
$5,872,227,000.00
Revenue This Year
$6.50
$12.45
Revenue Next Year
$6.71
$10.13
P/E Ratio
$63.47
$40.85
Revenue Growth
17.15
20.82
52 Week Low
$155.64
$541.00
52 Week High
$226.88
$859.34

Technical Indicators

Market Signals
Indicator
RTX
REGN
Relative Strength Index (RSI) 29.08 44.16
Support Level $192.36 $732.04
Resistance Level $205.11 $782.44
Average True Range (ATR) 3.64 19.05
MACD -1.54 -9.90
Stochastic Oscillator 11.98 5.05

Price Performance

Historical Comparison
RTX
REGN

About RTX RTX Corporation

RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure across three segments, mostly as a supplier to commercial aerospace and to the defense market: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Share on Social Networks: